Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms

Cancer Cell–Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti–PD-1 Therapy in Lung Adenocarcinoma

(2020) Amber M. Johnson et al.   JOURNAL OF IMMUNOLOGY

MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer

(2019) Mengyu Xie et al.   CANCER RESEARCH

Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab

(2018) Brandon W. Higgs et al.   CLINICAL CANCER RESEARCH

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma

(2018) Marielle E. Yohe et al.   Science Translational Medicine

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer

(2018) Amanda B. Pilling et al.   Oncotarget

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II

(2018) Howard Y. Li et al.   OncoImmunology

Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios

(2018) Rozina Aktar et al.   BRITISH JOURNAL OF RADIOLOGY

YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction

(2018) Chun-Hua Dai et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

A Beginner’s Guide to Analyzing and Visualizing Mass Cytometry Data

(2017) Abigail K. Kimball et al.   JOURNAL OF IMMUNOLOGY

Bone marrow-derived cPLA2α contributes to renal fibrosis progression

(2017) John R. Montford et al.   JOURNAL OF LIPID RESEARCH

Triple Angiokinase Inhibitor Nintedanib Directly Inhibits Tumor Cell Growth and Induces Tumor Shrinkage via Blocking Oncogenic Receptor Tyrosine Kinases

(2017) Frank Hilberg et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

(2017) Sarah K. Nelson-Taylor et al.   MOLECULAR CANCER THERAPEUTICS

Non-small-cell lung cancer cell lines A549 and NCI-H460 express hypoxanthine guanine phosphoribosyltransferase on the plasma membrane

(2017) Michelle Townsend et al.   OncoTargets and Therapy

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

(2017) Scott Gettinger et al.   Cancer Discovery

HDAC inhibitors enhance the immunotherapy response of melanoma cells

(2017) Laurence Booth et al.   Oncotarget

The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade

(2017) Howard Y. Li et al.   Cancer Immunology Research

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

(2016) Peter J.R. Ebert et al.   IMMUNITY

The repair capacity of lung cancer cell lines A549 and H1299 depends on HMGB1 expression level and thep53status

(2016) Shazie Yusein-Myashkova et al.   JOURNAL OF BIOCHEMISTRY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy

(2016) Douglas B. Johnson et al.   Nature Communications

Cytofkit: A Bioconductor Package for an Integrated Mass Cytometry Data Analysis Pipeline

(2016) Hao Chen et al.   PLoS Computational Biology

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies

(2014) M. W. Wynes et al.   CLINICAL CANCER RESEARCH

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system

(2014) Danilo Maddalo et al.   NATURE

Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma

(2013) Kelly A. Cycon et al.   IMMUNOLOGY

Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer

(2012) K. D. Davies et al.   CLINICAL CANCER RESEARCH

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

(2012) Jeffrey R Infante et al.   LANCET ONCOLOGY

The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers

(2011) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Expression Regulation of Major Histocompatibility Complex Class I and Class II Encoding Genes

(2011) Peter J. van den Elsen   Frontiers in Immunology

Depletion of Cytosolic Phospholipase A2 in Bone Marrow-Derived Macrophages Protects against Lung Cancer Progression and Metastasis

(2009) M. C.M. Weiser-Evans et al.   CANCER RESEARCH

MHC class II regulation by epigenetic agents and microRNAs

(2009) Thomas B. Tomasi et al.   IMMUNOLOGIC RESEARCH